NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
Recruiting · NCT06340516 · Registry updated 2024-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, cardiovascular disorder, heart disorder, injury, neoplasm, radiation injury, skin disorder | Recruiting | Not applicable | 2024-04-01 | NCT06340516 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vastra Gotaland Region | 163 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jubileumskliniken, Sahlgrenska University Hospital | Gothenburg | Sweden | 1 |